Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models

Neurobiology of Disease

Volumn 71, Issue 1, 2014, Pages 334-344

  Thiele, Sherri L ^a   Chen, Betty ^a   Lo, Charlotte ^a   Gertler, Tracey S ^c   Warre, Ruth ^a   Surmeier, James D ^c   Brotchie, Jonathan M ^b   Nash, Joanne E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BAC transgenic mouse models; Dyskinesia; Parkinson's disease; Slice electrophysiology; Striatum; Synaptic plasticity

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LEVODOPA; OXIDOPAMINE; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GREEN FLUORESCENT PROTEIN; PURINERGIC RECEPTOR AFFECTING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; EXCITABILITY; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOTOR CONTROL; MOUSE; MOUSE MODEL; NERVE CELL PLASTICITY; NONHUMAN; PARKINSONISM; TRANSGENIC MOUSE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETICS; HEMISPHERIC DOMINANCE; IN VITRO STUDY; METABOLISM; NERVE TRACT; NEWBORN; PARKINSONIAN DISORDERS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANIMALS, NEWBORN; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY POSTSYNAPTIC POTENTIALS; FUNCTIONAL LATERALITY; GREEN FLUORESCENT PROTEINS; IN VITRO TECHNIQUES; LEVODOPA; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONAL PLASTICITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PURINERGIC AGENTS; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D1;

EID: 84908213353     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.006     Document Type: Article

References (91)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Ahmed M.R., Berthet A., Bychkov E., Porras G., Li Q., Bioulac B.H., Carl Y.T., Bloch B., Kook S., Aubert I., Dovero S., DoudnikoffE., Gurevich V.V., Gurevich E.V., Bezard E. Lentiviral overexpression of GRK6 alleviates l-dopa-induced dyskinesia in experimental Parkinson's disease. Sci. Transl. Med. 2010, 2:28ra28.
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
4. Albin R.L., Young A.B., Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 1995, 18:63-64.
5. Anden N.E., Carlsson A., Kerstell J., Magnusson T., Olsson R., Roos B.E., Steen B., Steg G., Svanborg A., Thieme G., Werdinius B. Oral l-dopa treatment of parkinsonism. Acta Med. Scand. 1970, 187:247-255.
6. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
7. Cerovic M., Bagetta V., Pendolino V., Ghiglieri V., Fasano S., Morella I., Hardingham N., Heuer A., Papale A., Marchisella F., Giampà C., Calabresi P5., Picconi B., Brambilla R. Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) dependent striatal plasticity in l-DOPA-induced dyskinesia. Biol. Psychiatry 2014, (in press).
8. Berthet A., Porras G., DoudnikoffE., Stark H., Cador M., Bezard E., Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:4829-4835.
9. Beurrier C., Ben-Ari Y., Hammond C. Preservation of the direct and indirect pathways in an in vitro preparation of the mouse basal ganglia. Neuroscience 2006, 140:77-86.
10. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
11. Brotchie J.M. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann. Neurol. 2000, 47:S105-S112. (discussion S112-104).
12. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 2005, 20:919-931.
13. Brotchie J.M., Lee J., Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J. Neural Transm. 2005, 112:359-391.
14. Brotchie J.M., Mitchell I.J., Sambrook M.A., Crossman A.R. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 1991, 6:133-138.
15. Calon F., Dridi M., Hornykiewicz O., Bedard P.J., Rajput A.H., Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
16. Canals M., Burgueno J., Marcellino D., Cabello N., Canela E.I., Mallol J., Agnati L., Ferre S., Bouvier M., Fuxe K., Ciruela F., Lluis C., Franco R. Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Neurochem. 2004, 88:726-734.
17. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
18. Castrioto A., Lozano A.M., Poon Y.Y., Lang A.E., Fallis M., Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch. Neurol. 2011, 68:1550-1556.
19. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, (Supplement 41, Chapter 9: Unit 9 25).
20. Cenci M.A., Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
21. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
22. Crossman A.R. Neural mechanisms in disorders of movement. Comp. Biochem. Physiol. A Comp. Physiol. 1989, 93:141-149.
23. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 1990, 5:100-108.
24. Cui G., Jun S.B., Jin X., Pham M.D., Vogel S.S., Lovinger D.M., Costa R.M. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013, 494:238-242.
25. Dang M.T., Yokoi F., Yin H.H., Lovinger D.M., Wang Y., Li Y. Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15254-15259.
26. DeCoteau W.E., Thorn C., Gibson D.J., Courtemanche R., Mitra P., Kubota Y., Graybiel A.M. Learning-related coordination of striatal and hippocampal theta rhythms during acquisition of a procedural maze task. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5644-5649.
27. DeCoteau W.E., Thorn C., Gibson D.J., Courtemanche R., Mitra P., Kubota Y., Graybiel A.M. Oscillations of local field potentials in the rat dorsal striatum during spontaneous and instructed behaviors. J. Neurophysiol. 2007, 97:3800-3805.
28. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
29. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13:281-285.
30. Duty S., Henry B., Crossman A.R., Brotchie J.M. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1998, 150:223-234.
31. Eskow Jaunarajs K.L., George J.A., Bishop C. l-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience 2012, 218:243-256.
32. Fino E., Venance L. Spike-timing dependent plasticity in the striatum. Front Synaptic Neurosci. 2010, 2:6.
33. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., Wallach I., Nairn A.C., Surmeier D.J., Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
34. Franklin K.B.J.P.G. The Mouse Brain in Stereotaxic Coordinates 2007, Academic Press.
35. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
36. Gil S., Park C., Lee J., Koh H. The roles of striatal serotonin and l-amino-acid decarboxylase on l-DOPA-induced dyskinesia in a hemiparkinsonian rat model. Cell. Mol. Neurobiol. 2010, 30:817-825.
37. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 2003, 425:917-925.
38. Guigoni C., Bezard E. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in l-dopa-induced dyskinesia. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S64-S67.
39. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., Mach U., Stark H., Leriche L., Hakansson K., Bioulac B.H., Gross C.E., SokoloffP., Fisone G., Gurevich E.V., Bloch B., Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S25-S29.
40. Hawes S.L., Gillani F., Evans R.C., Benkert E.A., Blackwell K.T. Sensitivity to theta-burst timing permits LTP in dorsal striatal adult brain slice. J. Neurophysiol. 2013, 110:2027-2036.
41. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151:334-342.
42. Henry B., Crossman A.R., Brotchie J.M. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of l-dopa-induced dyskinesia. Adv. Neurol. 1998, 78:53-61.
43. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1999, 155:204-220.
44. 2+ influx by D2 dopamine and A2A adenosine receptors. Nat. Neurosci. 2010, 13:958-966.
45. Hornykiewicz O. Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man. Dtsch. Med. Wochenschr. 1962, 7:1807-1810.
46. Huot P., Johnston T.H., Koprich J.B., Fox S.H., Brotchie J.M. The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol. Rev. 2013, 65:171-222.
47. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities. Mov. Disord. 2008, 23(Suppl. 3):S585-S598.
48. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., Lundblad M., Cenci M.A. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 2004, 17:219-236.
49. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
50. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J. Neurosci. 2005, 25:10537-10545.
51. Kull B., Ferre S., Arslan G., Svenningsson P., Fuxe K., Owman C., Fredholm B.B. Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem. Pharmacol. 1999, 58:1035-1045.
52. Lerner T.N., Horne E.A., Stella N., Kreitzer A.C. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. J. Neurosci. 2010, 30:2160-2164.
53. Li L., Qiu G., Ding S., Zhou F.M. Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice. Brain Res. 2013, 1491:236-250.
54. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
55. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2004, 16:110-123.
56. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
57. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 2005, 194:66-75.
58. Maneuf Y.P., Crossman A.R., Brotchie J.M. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 1997, 148:265-270.
59. Maneuf Y.P., Mitchell I.J., Crossman A.R., Brotchie J.M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 1994, 125:65-71.
60. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C.E., Bezard E., Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 2006, 22:586-598.
61. Mitchell I.J., Sambrook M.A., Crossman A.R. Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 1985, 108(Pt 2):405-422.
62. Mitchell I.J., Jackson A., Sambrook M.A., Crossman A.R. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res. 1985, 339:346-350.
63. Morelli M., Di Paolo T., Wardas J., Calon F., Xiao D., Schwarzschild M.A. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 2007, 83:293-309.
64. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 2000, 165:136-142.
65. Navailles S., Lagiere M., Contini A., De Deurwaerdere P. Multisite intracerebral microdialysis to study the mechanism of l-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem. Neurosci. 2013, 4:680-692.
66. Pan H.S., Penney J.B., Young A.B. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem. 1985, 45:1396-1404.
67. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 1995, 701:13-18.
68. Park Y.S., Kim H.Y., Chang W.S., Lee P.H., Sohn Y.H., Chang J.W. A comparison of LEDD and motor scores following STN-DBS treatment in patient with young onset vs late onset Parkinson's disease. Neuromodulation 2010, 13:255-260.
69. Pawlak V., Kerr J.N. Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. J. Neurosci. 2008, 28:2435-2446.
70. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
71. Picconi B., Paille V., Ghiglieri V., Bagetta V., Barone I., Lindgren H.S., Bernardi G., Angela Cenci M., Calabresi P. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. 2008, 29:327-335.
72. Picconi B., Bagetta V., Ghiglieri V., Paille V., Di Filippo M., Pendolino V., Tozzi A., Giampa C., Fusco F.R., Sgobio C., Calabresi P. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011, 134:375-387.
73. Reynolds J.N., Hyland B.I., Wickens J.R. A cellular mechanism of reward-related learning. Nature 2001, 413:67-70.
74. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
75. Schiffmann S.N., Libert F., Vassart G., Vanderhaeghen J.J. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci. Lett. 1991, 130:177-181.
76. Schiffmann S.N., Dassesse D., d'Alcantara P., Ledent C., Swillens S., Zoli M. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology 2003, 61:S24-S29.
77. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
78. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999, 59:355-396.
79. Thiele S.L., Warre R., Nash J.E. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. J. Vis. Exp. 2012, 14:3234.
80. Thiele S.L., Warre R., Khademullah C.S., Fahana N., Lo C., Lam D., Talwar S., Johnston T.H., Brotchie J.M., Nash J.E. Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains. J. Neurosci. Methods 2011, 197:193-208.
81. Tort A.B., Kramer M.A., Thorn C., Gibson D.J., Kubota Y., Graybiel A.M., Kopell N.J. Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20517-20522.
82. Torvinen M., Marcellino D., Canals M., Agnati L.F., Lluis C., Franco R., Fuxe K. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol. Pharmacol. 2005, 67:400-407.
83. Torvinen M., Torri C., Tombesi A., Marcellino D., Watson S., Lluis C., Franco R., Fuxe K., Agnati L.F. Trafficking of adenosine A2A and dopamine D2 receptors. J. Mol. Neurosci. 2005, 25:191-200.
84. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
85. Utley J.D., Carlsson A. Relative effects of l-DOPA and its methyl ester given orally or intraperitoneally to reserpine-treated mice. Acta Pharmacol. Toxicol. 1965, 23:189-193.
86. Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., Quack G., Cenci M.A. Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia. J. Neurochem. 2007, 102:1395-1409.
87. Warre R., Thiele S., Talwar S., Kamal M., Johnston T.H., Wang S., Lam D., Lo C., Khademullah C.S., Perera G., Reyes G., Sun X.S., Brotchie J.M., Nash J.E. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol. Dis. 2011, 41:591-604.
88. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
89. Wichmann T., Bergman H., DeLong M.R. The primate subthalamic nucleus III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72:521-530.
90. Yin H.H., Mulcare S.P., Hilario M.R., Clouse E., Holloway T., Davis M.I., Hansson A.C., Lovinger D.M., Costa R.M. Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nat. Neurosci. 2009, 12:333-341.
91. Zeng B.Y., Pearce R.K., MacKenzie G.M., Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA. Eur. J. Neurosci. 2000, 12:1096-1104.